Zonisamide is a sulfonamide anticonvulsant primarily indicated for the treatment of epilepsy and Parkinson's disease. By modulating GABA activity and inhibiting carbonic anhydrase, this drug requires precise… Read more




![Chemical structure of Benzo[d]isoxazol-3-yl-methanesulfonyl chloride](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F73101-65-2-Benzodisoxazol-3-yl-methanesulfonyl-chloride.png&w=3840&q=75)
![Chemical structure of Benzo[d]isoxazol-3-ylmethanesulfonic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F342623-49-8-Benzodisoxazol-3-ylmethanesulfonic-Acid.png&w=3840&q=75)
![Chemical structure of Benzo[d]isoxazole-3-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F52046-80-7-Benzodisoxazole-3-carboxamide.png&w=3840&q=75)

![Chemical structure of N-(Benzo[d]isoxazol-3-yl)-N-methylmethanesulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-Benzodisoxazol-3-yl-N-methylmethanesulfonamide.png&w=3840&q=75)



















Zonisamide is a sulfonamide anticonvulsant primarily indicated for the treatment of epilepsy and Parkinson's disease. By modulating GABA activity and inhibiting carbonic anhydrase, this drug requires precise manufacturing controls to ensure patient safety and product efficacy. Pharmaceutical laboratories utilize this comprehensive selection of Zonisamide reference standards to support rigorous quality control and analytical method development. The range encompasses critical pharmacopeial and non-pharmacopeial impurities, including specific degradation products and related compounds, which are essential for performing accurate impurity profiling during stability testing. Additionally, stable isotope labelled Zonisamide compounds are provided to serve as robust internal standards for precise quantitative analysis and mass balance studies. These materials assist in the validation of analytical methods and help maintain compliance with regulatory requirements throughout the drug development lifecycle.